Why treatment of pre-RA isn't ready for prime time The ACR Great Debate was on "To treat or not to treat in pre-RA?" and it was stressed that autoimmunity may start well before clinical symptoms occur. https://t.co/TcKRc0w4i9 https://t.co/OkmlxTiAbm

Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression Dr. Lianne Gensler ( @lianegensler discusses the following abstracts presented at #ACR22. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes) https://t.co/f7o8UARKNl https://t.co/ryVmD86UoI

Systematic review of MSK findings in patients with acute lymphoblastic leukemia finds 29 pts with peripheral arthritis (7), axial manifestations (17), and osteolytic lesions (21 pts) & Vertebral Fx (4) Hypercalcemia in 9 cases. https://t.co/GJXoqhOjNG https://t.co/YHS09E4a0U

Tight control of proteinuria in newly diagnosed lupus nephritis The last 3 years have been exciting times in the field of lupus nephritis (LN) with two new licensed therapies, belimumab (BAFF-inhibitor) and voclosporin (calcineurin-inhibitor). https://t.co/Q7TahfZiB0 https://t.co/9Odwed55fe

Steroids in RA: Friend or foe (or both)? Abstract 2000 presents longer-term follow-up data from the recently published GLORIA trial. https://t.co/kNxwYMf59m https://t.co/rzRsZymlz3

RA: MACE Events with Opioids vs. NSAIDs The authors of abstract 1646 assessed MACE (myocardial infarction, stroke, heart failure, CVD death, VTE) and all-cause mortality in new users of opioids vs. matched NSAIDs new users. https://t.co/huz6NyYRlh https://t.co/dNYu7ybFZ5

Diffuse alveolar hemorrhage in antiphospholipid syndrome https://t.co/Fx2fGcaNGS https://t.co/jFHUhvs5xV

Eosinophilia in systemic JIA patients after exposure to biologics Dr. Bella Mehta discusses Abstract 0872 at #ACR22. https://t.co/FI7KfDURr3 https://t.co/FqnqMPHJ3h

Inadequate Dosing of Hydroxychloroquine Leads to Hospitalizations in SLE https://t.co/qJ8YbJ2Y6A https://t.co/deZKc1835I

Joint hypermobility linked to depression & anxiety? Longitudinal Study of 6105 kids at age 14 yrs: 19% had generalised joint hypermobility (more in F) *+& assoc w/ depression (OR: 3.53), anxiety (3.14) at age 18 https://t.co/9NrEfwt4L5 https://t.co/JrM2JKUuJ0

SLE preg delivery hospitalizations (77560) was associated with increased risk of CV complications, including preeclampsia [aOR 2.12] , peripartum cardiomyopathy (4.42), CHF (4), arrhythmias (2.2), AKI (7.7), stroke (4.8), VTE (6.9) w/ incr hosp costs https://t.co/PF6P8oDWZB https://t.co/jA2pHcciB1

Xeljanz Cancer Risks Detailed The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study. https://t.co/OG2OkD5Tcw https://t.co/1dZcJ5jDUj